최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기International journal of environmental research and public health, v.18 no.10, 2021년, pp.5114 -
Yang, Bo-Ram (College of Pharmacy, Chungnam National University, Daejeon 34134, Korea) , Heo, Kyu-Nam (br.yang@cnu.ac.kr) , Yu, Yun Mi (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea) , Yeom, Ga-Bin (bogopa8@snu.ac.kr) , Choi, Hye Duck (Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Korea) , Lee, Ju-Yeun (yunmiyu@yonsei.ac.kr) , Ah, Young-Mi (College of Pharmacy, Yeungnam University, Gyeongsan 38541, Korea)
Media has become a major source of information on health and plays a role in the decision-making process on health topics. We aimed to evaluate the association between zolpidem use and media broadcasts that reported the suicide risk. We obtained the data of adult outpatients who have been prescribed...
1. Jang Y. Song I. Oh I.-S. Shin J.-Y. Twelve-year trend in the use of zolpidem and physicians’ non-compliance with recommended duration: A Korean national health insurance database study Eur. J. Clin. Pharmacol. 2018 75 109 117 10.1007/s00228-018-2563-9 30280207
2. Schroeck J.L. Ford J. Conway E.L. Kurtzhalts K.E. Gee M.E. Vollmer K.A. Mergenhagen K.A. Review of Safety and Efficacy of Sleep Medicines in Older Adults Clin. Ther. 2016 38 2340 2372 10.1016/j.clinthera.2016.09.010 27751669
3. Darcourt G. Pringuey D. Sallière D. Lavoisy J. The safety and tolerability of zolpidem—An update J. Psychopharmacol. 1999 13 81 93 10.1177/026988119901300109 10221362
4. Qaseem A. Kansagara D. Forciea M.A. Cooke M. Denberg T.D. For the Clinical Guidelines Committee of the American College of Physicians Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians Ann. Intern. Med. 2016 165 125 133 10.7326/M15-2175 27136449
5. Donnelly K. Bracchi R. Hewitt J. Routledge P.A. Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis PLoS ONE 2017 12 e0174730 10.1371/journal.pone.0174730 28448593
6. Yang B.R. Kim Y.-J. Kim M.-S. Jung S.-Y. Choi N.-K. Hwang B. Park B.-J. Lee J. Prescription of Zolpidem and the Risk of Fatal Motor Vehicle Collisions: A Population-Based, Case-Crossover Study from South Korea CNS Drugs 2018 32 593 600 10.1007/s40263-018-0520-x 29796977
7. Stranks E.K. Crowe S.F. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: A systematic review and meta-analysis J. Clin. Exp. Neuropsychol. 2014 36 691 700 10.1080/13803395.2014.928268 24931450
8. Ram D. Eiman N. Gowdappa A.B. Multimodal Hallucination (Audio-visual, Kinaesthetic and Scenic) Associated with the Use of Zolpidem Clin. Psychopharmacol. Neurosci. 2015 13 215 217 10.9758/cpn.2015.13.2.215 26243852
9. Sun Y. Lin C.-C. Lu C.-J. Hsu C.-Y. Kao C.-H. Association Between Zolpidem and Suicide: A Nationwide Population-Based Case-Control Study Mayo Clin. Proc. 2016 91 308 315 10.1016/j.mayocp.2015.10.022 26776243
11. Choi B. Sung H.G. Nam J.H. Shin J. Zolpidem Use and Suicide Death in South Korea: A Population-Based Case–Control Study Suicide Life-Threat. Behav. 2018 49 1653 1667 10.1111/sltb.12548
12. SBS I Want to Know That Episode Devil’s Whispher-Who Is the Killer of the Serial Death Case Available online: https://programs.sbs.co.kr/culture/unansweredquestions/vod/55075/22000184573 (accessed on 3 January 2021)
13. Kim J.W. Jung H.Y. Won D.Y. Noh J.H. Shin Y.S. Kang T.I. Suicide Trends According to Age, Gender, and Marital Status in South Korea Omega-J. Death Dying 2017 79 90 105 10.1177/0030222817715756 28622733
14. EMA Guideline on Good Pharmacovigilance Practices (GVP) Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-2.pdf (accessed on 1 March 2021)
15. Norman J.L. Fixen D.R. Saseen J.J. Saba L.M. Linnebur S.A. Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes SAGE Open Med. 2017 5 10.1177/2050312117707687 28515934
16. Kesselheim A.S. Donneyong M. Pan G.J.D. Zhou E.H. Avorn J. Schneeweiss S. Seeger J.D. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications Pharmacoepidemiol. Drug Saf. 2017 26 712 721 10.1002/pds.4215 28449404
17. Touchard J. Sabatier P. Airagnes G. Berdot S. Consequences of the new zolpidem prescription regulations: A cohort study from the French national healthcare database Eur. J. Clin. Pharmacol. 2020 76 89 95 10.1007/s00228-019-02737-7 31608425
18. Park M.-J. Kim M.-H. Shin S.M. Chung S.Y. Effect of providing drug utilization review information on tricyclic antidepressant prescription in the elderly J. Med. Syst. 2018 42 1 10 10.1007/s10916-018-1061-z
19. Jung S. Jang E.J. Choi S. Im S.G. Kim D. Cho S. Kim H. Sung Y. Effect of a Nationwide Real-Time Drug Utilization Review System on Duplicated Nonsteroidal Antiinflammatory Drug Prescriptions in Korea Arthritis Rheum. 2020 72 1374 1382 10.1002/acr.24054
20. Barry C.L. Busch S.H. News Coverage of FDA Warnings on Pediatric Antidepressant Use and Suicidality Pediatrics 2009 125 88 95 10.1542/peds.2009-0792 19969614
21. Metlay J.P. Cohen A. Polsky D. Kimmel S.E. Koppel R. Hennessy S. Medication Safety in Older Adults: Home-Based Practice Patterns J. Am. Geriatr. Soc. 2005 53 976 982 10.1111/j.1532-5415.2005.53308.x 15935020
22. Grilli R. Ramsay C. Minozzi S. Mass media interventions: Effects on health services utilisation Cochrane Database Syst. Rev. 2002 CD000389 10.1002/14651858.CD000389 11869574
23. De Jesus M. The Impact of Mass Media Health Communication on Health Decision-Making and Medical Advice-Seeking Behavior of U.S. Hispanic Population Health Commun. 2012 28 525 529 10.1080/10410236.2012.701584 22888787
24. Waller P.C. Evans S.J.W. Beard K. Drug safety and the media Br. J. Clin. Pharmacol. 2006 61 123 126 10.1111/j.1365-2125.2005.02528.x 16433866
25. Rabi D.M. Lewin A.M. Brown G.E. Edwards A.L. Johnson J.A. Ghali W.A. Lay media reporting of rosiglitazone risk: Extent, messaging and quality of reporting Cardiovasc. Diabetol. 2009 8 40 10.1186/1475-2840-8-40 19630978
27. Owens S.R. Injection of confidence EMBO Rep. 2002 3 406 409 10.1093/embo-reports/kvf106 11991943
28. Sloane R. Osanlou O. Lewis D.A. Bollegala D. Maskell S. Pirmohamed M. Social media and pharmacovigilance: A review of the opportunities and challenges Br. J. Clin. Pharmacol. 2015 80 910 920 10.1111/bcp.12717 26147850
29. Viale P.H. Direct-to-Consumer Advertising of Prescription Medications: Implications for Patients with Cancer Oncol. Nurs. Forum 2002 29 505 513 10.1188/02.ONF.505-513 11979283
30. Fogel J. King K. Perceived Realism and Twitter Use Are Associated with Increased Acceptance of Cosmetic Surgery among Those Watching Reality Television Cosmetic Surgery Programs Plast. Reconstr. Surg. 2014 134 233 238 10.1097/PRS.0000000000000322 25068324
31. Kim L. Kim J.-A. Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples Epidemiol. Health 2014 36 e2014008 10.4178/epih/e2014008 25078381
32. Quan H. Sundararajan V. Halfon P. Fong A. Burnand B. Luthi J.-C. Saunders L.D. Beck C.A. Feasby T.E. Ghali W.A. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data Med. Care 2005 43 1130 1139 10.1097/01.mlr.0000182534.19832.83 16224307
33. Sobel R.E. Bate A. Marshall J. Haynes K. Selvam N. Nair V. Daniel G. Brown J.S. Reynolds R.F. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System’s analytic tools Pharmacoepidemiol. Drug Saf. 2018 27 332 339 10.1002/pds.4392 29392851
34. Kim H.M. Gerlach L.B. Yosef M. Stano C. Conroy D.A. Valenstein M. Pfeiffer P.N. Sales A.E. Zivin K. Responsiveness of Veterans Affairs Health Care System to Zolpidem Safety Warnings J. Clin. Sleep Med. 2018 14 1135 1141 10.5664/jcsm.7210 29991420
35. Kesselheim A.S. Sinha M.S. Rausch P. Lu Z. Tessema F.A. Lappin B.M. Zhou E.H. Pan G.J.D. Zwanziger L. Ramanadham A. Patients’ Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey J. Law Med. Ethic 2019 47 430 441 10.1177/1073110519876176
36. Fogel J. Shlivko A. Reality Television Programs Are Associated with Illegal Drug Use and Prescription Drug Misuse Among College Students Subst. Use Misuse 2015 51 62 72 10.3109/10826084.2015.1082593 26683767
37. Dopheide J.A. Insomnia overview: Epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy Am. J. Manag. Care 2020 26 S76 S84 10.37765/ajmc.2020.42769 32282177
38. Kesselheim A.S. McGraw S.A. Dejene S.Z. Rausch P. Pan G.J.D. Lappin B.M. Zhou E.H. Avorn J. Campbell E.G. Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study Drug Saf. 2017 40 531 542 10.1007/s40264-017-0516-3 28247279
39. Dusetzina S.B. Higashi A.S. Dorsey E.R. Conti R. Huskamp H.A. Zhu S. Garfield C.F. Alexander G.C. Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors Med. Care 2012 50 466 478 10.1097/MLR.0b013e318245a160 22266704
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.